-
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has entered into a strategic partnership with Wuhan Banbiantian Medical Technology Development Co., Ltd. The collaboration, which is centered around digitalization technologies, is designed to capitalize on the “medicine, device, drug” linkage model. While financial specifics…
-
Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced the receipt of a substantial grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSMIF). The grant will facilitate the expansion of Pharmaron’s existing viral vector and DNA manufacturing facility in Liverpool,…
-
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor of VEGFR-1, -2, and -3, fruquintinib. The drug is proposed for the treatment of refractory metastatic…
-
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
•
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics’ A shares and warrants to be traded on the NASDAQ under the ticker symbols “APLM” and “APLMW” respectively. The merger, which…
-
Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s Victoza (liraglutide). This new biosimilar is intended for use in treating patients with type 2 diabetes. Liraglutide…
-
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
•
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide drug candidate, as part of an ongoing licensing deal with US-based RayzeBio. The agreement aims to develop and commercialize the product in Greater China, expanding Ablaze’s portfolio and strengthening its commitment to cancer therapies. Licensing…
-
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study of its novel small molecule chemical drug, FCN-159. The study will evaluate the drug’s efficacy as a treatment…
-
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company, has announced the start of a Phase III clinical study in the Chinese mainland for its HER2-targeted antibody drug conjugate (ADC), FS-1502. The study is focused on the treatment of HER2-positive unresectable, locally advanced, or…
-
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered into a strategic partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) and Indonesian pharmaceutical company Combiphar. The collaboration aims to strengthen the cooperation between China and Indonesia in the vaccine sector. Under the terms of the…
-
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology (JCO) has published the results of the registrational clinical study GEMSTONE-201 for the PD-L1 antibody sugemalimab in the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). This study represents the largest registrational clinical…
-
SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal
•
China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO)…
-
Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade
•
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi in its inaugural funding round, which was exclusively led by Delian Capital. The capital raised will be directed towards enhancing QL Bio’s “one-stop proteomics platform” and advancing the discovery and clinical application of protein biomarkers.…
-
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
•
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for its potentially groundbreaking oncolytic virus product, MVR-C5252, which is under development to treat gliomas. This first-in-class product marks a significant step forward in the treatment of brain tumors. Global Context and PrecedenceIn June 2021, Japanese…
-
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
•
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development…
-
Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial
•
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its respiratory syncytial virus (RSV) adult vaccine development program, which includes discontinuing a Phase III trial. This strategic move is a response to the current RSV vaccine landscape and is part of an effort to optimize…
-
Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total revenue of RMB 5.982 billion (USD 869.8 million), marking a 15.0% year-on-year (YOY) increase. The company’s performance reflects significant growth, particularly in its tumor treatment sector, which saw a 63.1% increase to RMB 2.306 billion…
-
Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib, a Janus kinase 3 (JAK3) inhibitor, is on track for priority review status for the treatment of vitiligo in China. This development highlights the potential fast-track approval process for this novel therapy in addressing the…
-
Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope
•
Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced a partnership agreement with China-based Scivita Medical Technology Co., Ltd. The collaboration pertains to the development of a disposable electronic choledochoscope, although no financial details have been disclosed. Boston Scientific’s Extensive Business Presence in ChinaBoston…
-
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
•
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab), a humanized ADCC-enhanced anti-Claudin 18.2 monoclonal antibody (mAb), has received orphan drug designation (ODD) status from the US FDA for the treatment of pancreatic cancer. This follows a previous ODD granted in 2021 for the…
-
CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health
•
China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the Chinese Center for Disease Control and Prevention (CDC). This collaboration aims to enhance various aspects of disease prevention and public health development in China, marking a significant step forward in the nation’s healthcare strategy. Areas…
